home

Overview - FIXX US

Homology Medicines
FIXX.US | summary | financial summary | prediction chart | global stock news | news graph | compare | components | pairs | earnings
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
symbollastchange%chngnamemcapsectorwiki
FIXX Homology Medicines Inc 0.493B Healthcare

symbolprev.closerangecharttargetpercentperiodmonthsduerating
 B  FIXX 2.45 0,-0.102,-0.970,0.732,-0.102 1.88,1.62,1.51,1.45,1.55,2.13,1.85,2.06,1.94,2.08,2.23,2.34,2.32,2.55,2.94 2.97-3.49 31.90% 267,127,267 4.7 5Apr-28Dec 60.65%
Intraday chart for FIXX

Please reload the page if latest figures not showing

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The arrows show the how the AI thinks the figure affects the stock price (not the change in the figure)

. operatingIncome -38M
. . netInterestIncome 0M
. incomeBeforeTax 94M
. otherOperatingExpenses 38M  
. netIncomeApplicableToCommonShares 92M
. reconciledDepreciation 0M
. netWorkingCapital 242M  
. netInvestedCapital 266M
. netDebt -224M  
. totalCashFromOperatingActivities -31M  
. freeCashFlow. . -32M  

Chart FIXX
BeiGene Ltd BGNE US Healthcare 24.8804 35824M -
argenx SE ARGX US Healthcare 30.5813 15863M -
Intellia Therapeutics Inc NTLA US Healthcare 34.3129 10960M -
Ascendis Pharma A/S ASND US Healthcare 30.3054 9322M -
CRISPR Therapeutics AG CRSP US Healthcare 36.4419 8872M -
Biohaven Pharmaceutical Holding Company Ltd BHVN US Healthcare 46.8683 8723M -
Denali Therapeutics Inc DNLI US Healthcare 65.694 6204M -
Fate Therapeutics Inc FATE US Healthcare 35.8753 6173M -
Allakos Inc ALLK US Healthcare 65.2213 5841M -
Editas Medicine Inc EDIT US Healthcare 34.4269 4008M -

Myshare aims to provide good clear honest and easy analysis of financial markets using a scientific, teaching and informative approach. We try hard but please read our disclaimer. Pages are provided by ourselves and our users. Register to edit pages and see the documentation

Global news | headline news | recent news | latest news | market news | topics | stock topics
News topics and stories from around the world and in the selected country

US News | headline news | recent news | latest news | market news | recent topics | stock topics
News from major news outlets like BBC, CNN and Reuters

Forecasts | Forecast buy | Forecast sell | Forecast up | Forecast down | Forecast sector
Long term stock predictions using AI reading the financial accounts of each company.

Ai Predictions | Buys | All up | sell | all down | forecast | History

``` ``` ``` ```